Green Cross Health Is Up 75% in a Year, Yet Analysts Still See 50% More Upside
Green Cross Health Is Up 75% in a Year, Yet Analysts Still See 50% More Upside
Green Cross Health has been one of the best performers on the NZX over the past year, climbing 74% and more than doubling from its 52-week low. The community pharmacy and primary care operator now trades around $1.49, yet it still carries a price-to-earnings ratio of just 12 times and pays a gross dividend yield above 5%. For investors searching for a healthcare name with both momentum and value, this is a rare combination on the local exchange.
Recent Performance
Green Cross Health shares closed recently at $1.485, just a few cents shy of their 52-week high of $1.54. The 52-week low of $0.73 was set roughly a year ago, meaning anyone who bought at the bottom has seen their investment roughly double.
The journey has not been a straight line. For much of the past year the stock oscillated between $0.75 and $0.90 before breaking decisively above $1.00 in early 2026. Volume spiked dramatically in April when the company confirmed it was in talks to sell its medical division. On one session during that period more than 935,000 shares changed hands, roughly 70 times the average daily turnover, as investors priced in the possibility of a deal.
Key Metrics
Green Cross Health is capitalised at roughly $213 million on the NZX, making it a small-cap healthcare play compared with giants like [Fisher & Paykel Healthcare](/stocks/fisher-paykel-healthcare). The key numbers from NZX data as of mid-May 2026 are:
- •Share price: $1.485
- •52-week range: $0.73 to $1.54
- •Market cap: ~$213 million
- •P/E ratio: 12.2
- •EPS: $0.122
- •Gross dividend yield: 5.4%
The valuation stands out. A P/E of 12 is well below the average for healthcare stocks globally, and the 5.4% yield is backed by consistent dividend payments rather than speculative promise. According to Stockopedia, the analyst consensus target price sits at $2.20, implying roughly 48% upside from current levels. Our [methodology](/methodology) page explains how we weigh analyst targets against other signals.
The Big Picture
Green Cross Health operates more than 300 Unichem and Life Pharmacy stores across New Zealand, giving it a presence in almost every community. On top of the retail pharmacy network, the company runs 65 medical centres under The Doctors brand, caring for over 400,000 enrolled patients. This makes it one of the largest primary healthcare providers in the country.
The recent share price rally has been fuelled by corporate activity as much as earnings. In mid-April 2026, Green Cross confirmed it was in talks with Sydney-based private equity firm Adamantem Capital regarding a potential sale of the Medical division. The announcement followed an Australian media report and came with the standard caveat: "There is no certainty that this engagement will lead to any transaction."
If a deal does proceed, it would not be the first time private equity has snapped up a New Zealand primary care asset. Earlier in 2026, US buyout giant TPG acquired Tamaki Health for a reported $500 million, showing that global investors are willing to pay significant multiples for GP clinic networks. Deloitte Corporate Finance is advising Green Cross on the process.
From an operational standpoint, the company's first-half 2026 results showed revenue of $264.4 million, up 1.8% from the prior year, while net income rose 27% to $7.19 million. The pharmacy division, which generates the bulk of sales, saw stable revenue but a 14% drop in operating profit, while the smaller medical division outperformed. Full-year revenue is expected to come in around $524 million with net profit near $16 million, based on company disclosures.
What to Watch
There are four main catalysts investors should monitor over the coming months.
1. The medical division sale outcome
A successful transaction could unlock significant value, potentially allowing Green Cross to return capital to shareholders or pay down debt. However, if talks collapse, the share price could retrace some of its recent gains. The company has said it will update the market as required under continuous disclosure obligations.
2. Full-year earnings on May 27
Green Cross is scheduled to report its full-year 2026 results on May 27. Investors will want to see whether the pharmacy margin pressure seen in the first half continued into the second half, or whether cost controls and government funding adjustments helped stabilise profitability.
3. Government primary care policy
With private equity circling the sector, there is growing scrutiny of government funding for general practice. Any changes to capitation rates or pharmacy reimbursement could flow directly to Green Cross's bottom line. The company has previously called for increased government support for primary healthcare.
4. The broader NZ healthcare landscape
Green Cross is not the only healthcare stock on the NZX facing a crossroads. [Ebos Group](/stocks/ebos-group), the country's largest healthcare distributor, has its own turnaround story, while aged care operators like [Oceania Healthcare](/stocks/oceania-healthcare) are navigating occupancy and staffing challenges. Sector-wide trends in funding, labour costs, and patient volumes will affect all of them.
The Bottom Line
The bull case for Green Cross Health is straightforward: the stock is cheap on a P/E basis, pays an attractive dividend, and could receive a significant catalyst if the medical division is sold at a favourable valuation. The bear case is that much of the good news may already be priced in after a 74% run, and the pharmacy division is battling margin pressure in a tough retail environment. For patient investors, the risk-reward looks reasonable at these levels, but anyone buying now should be prepared for volatility if the sale talks fall through.
*This article is for informational purposes only and does not constitute financial advice. Past performance is not a reliable indicator of future results. Always do your own research or consult a licensed financial adviser before making investment decisions.*